ReShape Lifesciences (RSLS) said Thursday it will implement a reduction in force that is expected to save more than $750,000 or about 23% of its annual payroll expenses.
Chief Executive Officer Paul Hickey said the company's sales and marketing team remains fully intact.
Hickey also said that the company is progressing towards finalizing the merger agreement with Vyome Therapeutics and the asset sale to Biorad Medisys, with a special shareholder meeting to vote on the transactions set for July 24.
Price: 2.47, Change: +0.01, Percent Change: +0.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments